MRT-2359 is a small molecule commercialized by Monte Rosa Therapeutics, with a leading Phase II program in Small-Cell Lung Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of MRT-2359’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for MRT-2359 is expected to reach an annual total of $120 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
MRT-2359 is under development for the treatment of solid tumors including small-cell lung cancer, non-small cell lung cancer, diffuse large B-cell lymphoma, multiple myeloma (Kahler disease), neuroendocrine cancer including prostate cancer. The drug candidate is a molecular glue degrader selectively targeting GSPT1. It is administered orally and is being developed based on Quantitative and Engineered Elimination of Neosubstrates (QuEEN) platform.
Monte Rosa Therapeutics Overview
Monte Rosa Therapeutics is a biotechnology company developing small molecules to degrade disease-related proteins. The company is headquartered in Boston, Massachusetts, the US.
The operating loss of the company was US$112.4 million in FY2022, compared to an operating loss of US$72.9 million in FY2021. The net loss of the company was US$108.5 million in FY2022, compared to a net loss of US$74 million in FY2021.
For a complete picture of MRT-2359’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.